Matches in Nanopublications for { ?s ?p "[This study investigated the therapeutic potential of a BRAF(V600E)-selective inhibitor, PLX4032 (RG7204), for thyroid cancer by examining its effects on the MAP kinase signaling and proliferation of 10 thyroid cancer cell lines with wild-type BRAF or BRAF(T1799A) mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 8 of
8
with 100 items per page.
- NP769192.RAuUWmu8YSzonxAZdz1bK9UCHUQaesMoBQcRpACPhF3Bk130_assertion description "[This study investigated the therapeutic potential of a BRAF(V600E)-selective inhibitor, PLX4032 (RG7204), for thyroid cancer by examining its effects on the MAP kinase signaling and proliferation of 10 thyroid cancer cell lines with wild-type BRAF or BRAF(T1799A) mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP769192.RAuUWmu8YSzonxAZdz1bK9UCHUQaesMoBQcRpACPhF3Bk130_provenance.
- NP918656.RAYZUSOGflh_dxvnMbPdxy8qg7dtqFTQwrUQr035aku8I130_assertion description "[This study investigated the therapeutic potential of a BRAF(V600E)-selective inhibitor, PLX4032 (RG7204), for thyroid cancer by examining its effects on the MAP kinase signaling and proliferation of 10 thyroid cancer cell lines with wild-type BRAF or BRAF(T1799A) mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP918656.RAYZUSOGflh_dxvnMbPdxy8qg7dtqFTQwrUQr035aku8I130_provenance.
- NP243924.RAzyfyQ7n4RJ4FBb3RYSVo_sN6otSZIT-oLA79O6sfdPo130_assertion description "[This study investigated the therapeutic potential of a BRAF(V600E)-selective inhibitor, PLX4032 (RG7204), for thyroid cancer by examining its effects on the MAP kinase signaling and proliferation of 10 thyroid cancer cell lines with wild-type BRAF or BRAF(T1799A) mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP243924.RAzyfyQ7n4RJ4FBb3RYSVo_sN6otSZIT-oLA79O6sfdPo130_provenance.
- NP568726.RA1eSx_Jz7MPL0xE89OKrNOnYDyeHYNABAPBJO6DYBAwI130_assertion description "[This study investigated the therapeutic potential of a BRAF(V600E)-selective inhibitor, PLX4032 (RG7204), for thyroid cancer by examining its effects on the MAP kinase signaling and proliferation of 10 thyroid cancer cell lines with wild-type BRAF or BRAF(T1799A) mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP568726.RA1eSx_Jz7MPL0xE89OKrNOnYDyeHYNABAPBJO6DYBAwI130_provenance.
- NP890264.RARA28ayZiVEmDAO9SwTohUejIMO8c58y80YAXIcyX6jo130_assertion description "[This study investigated the therapeutic potential of a BRAF(V600E)-selective inhibitor, PLX4032 (RG7204), for thyroid cancer by examining its effects on the MAP kinase signaling and proliferation of 10 thyroid cancer cell lines with wild-type BRAF or BRAF(T1799A) mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP890264.RARA28ayZiVEmDAO9SwTohUejIMO8c58y80YAXIcyX6jo130_provenance.
- NP861569.RAfHwNPqFwwDK19lzsnUdi71sKZ9QIZpqaV5GwAmk2SoI130_assertion description "[This study investigated the therapeutic potential of a BRAF(V600E)-selective inhibitor, PLX4032 (RG7204), for thyroid cancer by examining its effects on the MAP kinase signaling and proliferation of 10 thyroid cancer cell lines with wild-type BRAF or BRAF(T1799A) mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP861569.RAfHwNPqFwwDK19lzsnUdi71sKZ9QIZpqaV5GwAmk2SoI130_provenance.
- NP890083.RAF3Ny0yQTraU5Ng4cAtJloqb420XhWkU9HKxDGsYgRJQ130_assertion description "[This study investigated the therapeutic potential of a BRAF(V600E)-selective inhibitor, PLX4032 (RG7204), for thyroid cancer by examining its effects on the MAP kinase signaling and proliferation of 10 thyroid cancer cell lines with wild-type BRAF or BRAF(T1799A) mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP890083.RAF3Ny0yQTraU5Ng4cAtJloqb420XhWkU9HKxDGsYgRJQ130_provenance.
- NP861573.RAyjJodfI7F6M9-fsdvnXmY0kB_oXRhB5bzBoPDaMgC2s130_assertion description "[This study investigated the therapeutic potential of a BRAF(V600E)-selective inhibitor, PLX4032 (RG7204), for thyroid cancer by examining its effects on the MAP kinase signaling and proliferation of 10 thyroid cancer cell lines with wild-type BRAF or BRAF(T1799A) mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP861573.RAyjJodfI7F6M9-fsdvnXmY0kB_oXRhB5bzBoPDaMgC2s130_provenance.